MorphoSys AG Logo

MorphoSys AG

MOR | F

Overview

Corporate Details

ISIN(s):
DE000A3H2XW6
LEI:
529900493806K77LRE72
Country:
Germany
Address:
Semmelweisstr. 7, 82152 Planegg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MorphoSys AG is a global biopharmaceutical company focused on developing innovative cancer therapies. Founded in 1992, the company specializes in creating fully human monoclonal antibodies for therapeutic and research applications. It utilizes various proprietary antibody, protein, and peptide technologies to discover and advance both its own and partnered drug candidates, with a particular emphasis on treatments for blood cancers like leukemia. The company's business model has included both drug development and licensing its technology platforms to pharmaceutical partners. In 2024, Novartis completed its acquisition of MorphoSys, integrating the company's oncology pipeline and antibody expertise.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for MorphoSys AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-08-27 16:00
Post-Annual General Meeting Information
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual G…
English 11.5 KB
2024-08-05 07:30
Delisting Announcement
MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and N…
English 12.1 KB
2024-07-19 16:46
Pre-Annual General Meeting Information
MorphoSys AG: Korrektur: Bekanntmachung der Einberufung zur Hauptversammlung am…
German 259.7 KB
2024-07-19 15:07
Pre-Annual General Meeting Information
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.08.2024…
German 259.7 KB
2024-07-18 16:00
Declaration of Voting Results & Voting Rights Announcements
English 4.6 KB
2024-07-12 22:02
Delisting Announcement
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
English 13.2 KB
2024-07-12 14:34
Legal Proceedings Report
Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
English 12.6 KB
2024-07-05 16:00
Report Publication Announcement
English 3.9 KB
2024-07-02 16:00
Major Shareholding Notification
English 14.6 KB
2024-06-21 16:00
Declaration of Voting Results & Voting Rights Announcements
English 14.3 KB
2024-06-20 08:25
Delisting Announcement
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merge…
English 21.4 KB
2024-06-20 08:06
M&A Activity
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of …
English 12.3 KB
2024-06-10 16:01
Major Shareholding Notification
English 13.4 KB
2024-06-10 16:00
Declaration of Voting Results & Voting Rights Announcements
English 13.4 KB
2024-06-06 22:19
Board/Management Information
Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of Morp…
English 10.9 KB

Automate Your Workflow. Get a real-time feed of all MorphoSys AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for MorphoSys AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-09-20 Cluzel, Dr. Marc Supervisory board Buy None 775.25 EUR
2023-06-07 Cluzel, Dr. Marc Supervisory board Buy None 52,800.00 EUR
2023-06-06 Cluzel, Dr. Marc Supervisory board Buy None 24,280.00 EUR
2022-11-30 Reissner, Thomas Supervisory board Buy None 13,800.00 EUR
2022-11-30 Reissner, Thomas Supervisory board Buy None 7,479.00 EUR
2022-11-30 Reissner, Thomas Supervisory board Buy None 4,186.00 EUR
2022-11-30 Reissner, Thomas Supervisory board Buy None 2,698.00 EUR
2022-11-29 Reissner, Thomas Supervisory board Buy None 8,100.00 EUR
2022-11-29 Reissner, Thomas Supervisory board Buy None 5,000.00 EUR
2022-11-28 Vermeylen, Krisja Supervisory board Buy None 14,860.00 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN